RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Charles and Lynn Schusterman Family Philanthropies
C

Charles and Lynn Schusterman Family Philanthropies portfolio

Charles and Lynn Schusterman Family Philanthropies has 2 portfolio companies on record at Recent Funding. It led 1 of the 2 rounds it joined. Its most recent investment on record is ConcertoCare's $105M Series B+ round in February 2022, alongside Wells Fargo Strategic Capital, Vast Ventures, SteelSky Ventures and 3 others. By category, its portfolio leans toward Health and bio (2) and Insurance (1). It has co-invested with Obvious Ventures, Deerfield and Wells Fargo Strategic Capital.

Type: Investor.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 0.
Rounds led: 1 of 2.
Capital in their rounds: $165M.
Latest deal: ConcertoCare · Feb 3, 2022.

What Charles and Lynn Schusterman Family Philanthropies invests in

How Charles and Lynn Schusterman Family Philanthropies invests

StageDealsCapital in rounds
Series B+ 1 50%$105M
Series A 1 50%$60M
YearDealsCapital in rounds
2021 1 50%$60M
2022 1 50%$105M

Share is of the 2 rounds on Recent Funding that name Charles and Lynn Schusterman Family Philanthropies. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Charles and Lynn Schusterman Family Philanthropies portfolio companies

CompanyRound with Charles and Lynn Schusterman Family PhilanthropiesTotal raisedLatest raise
CConcertoCare
Insurance
Series B+ · $105M$105MFeb 3, 2022
Series B+
IImmunai
Health and bio
Series A · $60M · lead$295MOct 28, 2021
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

Portfolio companies are the companies on Recent Funding with a round that lists Charles and Lynn Schusterman Family Philanthropies, which is a subset of its real portfolio. API: /api/v1/investors/charles-and-lynn-schusterman-family-philanthropies (get a free API key). More: the most active VC firms and new venture capital funds.